Company

Radius Health, Inc.

Headquarters: Waltham, MA, United States

Employees: 293

CEO: Mr. G. Kelly Martin

NASDAQ: RDUS -1.60%

Market Cap

$480.0 Million

USD as of Aug. 1, 2022

Market Cap History

Radius Health, Inc. market capitalization over time

Evolution of Radius Health, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Radius Health, Inc.

Detailed Description

Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts.

Top 1-year algo backtest: +298.72%

$10,000 in April 2023 would now be $39,872 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Radius Health, Inc. has the following listings and related stock indices.


Stock: NASDAQ: RDUS wb_incandescent

Stock: FSX: 1R8 wb_incandescent

Details

Headquarters:

950 Winter Street

Waltham, MA 02451

United States

Phone: 617 551 4000

Fax: 617 551 4701